Rivastigmine Market - Size, Share, Outlook,
and Opportunity Analysis, 2018- 2026
Rivastigmine is a cholinesterase enzyme inhibitor, which acts on butylcholinesterase and
acetylcholinesterase. It is a cholinergic agent that aids in the treatment of Alzheimer’s and
Parkinson’s disease. The drug can be administered orally or in transdermal patches form, owing to
its small molecular size.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/2407
Rivastigmine Market – Dynamics
Increasing geriatric population is a major driver for growth of the rivastigmine market. According to
The Alzheimer Association, in 2018, the risk of suffering from dementia can increase double fold
above the age of 65 years in every 5 years. Moreover, increasing prevalence of cardiovascular
diseases worldwide also accounts for the development of Alzheimer’s disease, thereby boosting
demand for rivastigmine. As per the National Center for Biotechnology Information published in
2013, the incidence of cardiovascular diseases was around 22.5 per 1,000 person worldwide which
in turn suggesting a risk of dementia.Diseases such as diabetes and blood pressure can also increase
the risk of dementia, which further boosts demand for rivastigmine, thereby propelling the market
growth.
Rivastigmine Market – Regional Insights
The rivastigmine market is segregated geographically into North America, Latin America, Asia
Pacific, Europe, Middle East, and Africa. North America accounted for the largest share in the